Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
Express News | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Med Initiated at Outperform by Baird
Praxis Precision Med Initiated at Outperform by Baird
Express News | Praxis Precision Medicines Inc : Baird Initiates Coverage With Outperform Rating; Price Target $117
Express News | HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target
Praxis Precision Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 98.56% HC Wainwright & Co. → $105 Reiterates Buy → Buy 03/26/2024 142.06% Jefferies $75 → $128
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
10:26 AM EDT, 04/08/2024 (MT Newswires) -- Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating Price: 51.07, Change
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0653 ET - Praxis Precision Medicines cashes in on a surge in i
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)
Praxis Uses Rising Stock Price to Top Off Coffers -- Market Talk
06:53 ET - Praxis Precision Medicines cashes in on a surge in its stock price to raise $200 million in an upsized public offering. The clinical-stage biopharmaceutical company sells more than 3.5 mill
Express News | Praxis Precision Medicines Priced $200M Offering of 3.3M Shares at $56.50/Share
Piper Sandler, Guggenheim Securities Among Managers for Praxis Offering >PRAX
Piper Sandler, Guggenheim Securities Among Managers for Praxis Offering >PRAX
Praxis Also Offering Pre-funded Warrants for 221,238 Shares >PRAX
Praxis Also Offering Pre-funded Warrants for 221,238 Shares >PRAX
Praxis Offering Expected to Close on or About April 2 >PRAX
Praxis Offering Expected to Close on or About April 2 >PRAX
Praxis Has Granted Underwriters Option for Up to 530,973 Additional Shares >PRAX
Praxis Has Granted Underwriters Option for Up to 530,973 Additional Shares >PRAX
No Data